Newsletter · 2026-07-17 · Ashutosh Agarwal

UnitedHealth Beats and Reignites the Insurer Debate as Weight-Loss Drugs Get Cheaper - The Healthcare Pulse - Week of July 17, 2026

Healthcare podcast intelligence for the week of July 17, 2026. UnitedHealth's blowout quarter pulled the whole market higher and reopened the Medicare Advantage debate, even as weight-loss drugs turn cheaper and more global and the dealmaking boom stretches into psychedelics.

The Healthcare Pulse

Week of July 17, 2026: UnitedHealth Beats and Reignites the Insurer Debate as Weight-Loss Drugs Get Cheaper

What healthcare investors, executives, and doctors were saying on podcasts, week of July 10–17, 2026.

This Week at a Glance

This was earnings week, and one number reset the mood in healthcare: UnitedHealth, the giant insurer whose stock had been left for dead a year ago, blew past expectations and told investors the turnaround is real. That single report pulled the whole Dow higher on Thursday and reopened one of the sector's biggest debates. Around it, five themes ran through the week's podcasts and news.

• The insurers came roaring back, and reignited a fight about how they make their money. UnitedHealth's huge earnings beat and raised forecast lit up the market. Portfolio managers called it a bargain and a turnaround story. But on a separate podcast, a former head of Medicare laid out, in detail, why he thinks the entire Medicare Advantage business is overpaid by tens of billions a year. Both conversations happened the same week.

• The weight-loss drug story entered a new phase: cheaper, broader, and global. The debate has moved past "do they work" to "what happens when prices fall." Morgan Stanley's pharma analyst walked through what's already happening in India, where cheap copies have exploded volumes, and what it means for the U.S. Meanwhile a brand-new Medicare program started covering the drugs for a $50 copay.

• The dealmaking boom kept going, and got weirder. Eli Lilly agreed to buy a psychedelics company. Vertex spent nearly $10 billion on a rare-disease drugmaker. The engine behind all of it: big drug companies racing to replace medicines that will soon lose patent protection.

• The middlemen of the drug system were on the defensive. A retired pharma executive laid out how the pharmacy "middlemen" capture more than half of every dollar spent on drugs, and one of the largest of those middlemen, OptumRx, announced a new pricing model designed to answer exactly that criticism.

• Two big science stories cut in opposite directions. A large heart-drug trial from AstraZeneca failed and wiped out billions in expected sales, a reminder of how brutal the downside can be. At the same time, psychedelic medicines, home-injectable Alzheimer's drugs, and AI-guided cancer care all took real steps forward.

A note on this week's mix: the richest podcast material was in obesity drugs, drug-pricing and insurance policy, biotech dealmaking, and the science pipeline. Direct stock-picking debate on the big pharmaceutical names (Pfizer, Merck, Amgen and the like) was thin on podcasts this week, so those views showed up mostly in analyst notes and news, and the stock-specific sections lean on both, and we flag it where it matters.

The People Driving the Conversation

Stephanie Link, portfolio manager, on why UnitedHealth is still cheap. The week's loudest single stock was UnitedHealth ($UNH), and the news broke live on air. On Morning Call (July 16), the company's earnings hit the wire mid-interview, shares jumped about 5%, worth roughly 140 points on the Dow all by themselves, and portfolio manager Stephanie Link, who owns the stock, made the bull case in real time:

"Helmsley, the CEO, is a rock star. And he's turning this company around. They repriced all of their membership when he got there... And they are also laser-focused on cost cuts and discipline... this stock is still value. It's like trading at 17 times earnings and about 18 times EBITDA. And this historically has traded in the 20s. So I like it. I think you should buy it. And I might even buy some more."

(In plain terms: she's arguing you're paying about 17 years' worth of current profit for the stock, versus the low-20s multiple it used to command, cheap for a company she thinks is fixing itself.) The company's own chief financial officer, on Squawk on the Street (July 16), framed it as a multi-year comeback built on repricing plans, dropping unprofitable contracts, and, notably, $1.5 billion invested in AI to cut costs.

Dr. Don Berwick, former head of Medicare, on why he thinks that same business is fundamentally overpaid. The counterweight came on TCN Talks (July 10), where Dr. Don Berwick, who ran the federal Medicare and Medicaid agency, gave a long, blunt history of Medicare Advantage (the private version of Medicare that insurers like UnitedHealth run). His core charge is that insurers "upcode," record patients as sicker than they are to collect bigger government payments:

"Medicare Advantage for the same patient was getting paid $80 billion a year more than traditional Medicare... they were supposed to be 5% or 6% cheaper with better care. Instead, they're 10% or more, 17% depending on the plan. And when you looked at the details... they just upcode everybody. You know, 50% of the patients in one large Medicare Advantage plan were coded as having peripheral vascular disease, which, ka-ching, you know, added nearly $3,000 a year to payment for them."

He tied that directly to the stock: when Washington began cracking down on those codes, "UnitedHealthcare... stock fell, I think, nearly 50%." His warning: "believe me, this isn't over. The amount of money being made in this Medicare Advantage gaming world is just phenomenal." Read side by side, the two podcasts capture the whole UnitedHealth debate: a genuine operational turnaround happening inside a business model that a former regulator says is built on overpayment.

Terence Flynn and Thibault Boutherin of Morgan Stanley, on the next phase of the weight-loss boom. On Thoughts on the Market (July 13), Morgan Stanley's U.S. and European pharma analysts laid out what happens to the obesity-drug market as cheap copycats arrive. The live experiment is India, where the patent on semaglutide (the ingredient in Ozempic and Wegovy) expired in March 2026:

"13 companies have launched 26 generics... the volume in April 2026 were already six times higher than the volume in February. And that expansion has been driven mostly by this generics launch, which captured 80% of semaglutide volume in April. And our India team expect that the GLP-1 market in India will actually expand in value from $125 million in [20]25 to more than $1 billion by 2030, despite lower prices."

The reassuring takeaway for investors in Eli Lilly and Novo Nordisk: patents in the U.S. don't expire until 2032 (2031 in Europe), and even when generics arrive, Flynn expects the market to split, with patients paying up for the newer, more effective tirzepatide (the ingredient in Mounjaro and Zepbound), which already holds about 60% of the U.S. market. He also flagged the near-term U.S. growth driver: starting this summer, Medicare patients over 65 can get the drugs for $50 a month, which "will broaden access to about an additional 18 million people."

Kate Molander, a senior OptumRx executive, on trying to defuse the "middleman" attack. Pharmacy-benefit managers, or PBMs, the companies that sit between drugmakers and patients and decide which drugs your insurance covers, are the villains of most drug-pricing stories. On Prescription for Better Access (July 15), a senior executive at OptumRx (one of the three giant PBMs, owned by UnitedHealth) announced a new pricing model meant to answer the central complaint, that PBMs profit more when drug prices rise:

"What our new announcement is, is to pass through every source of revenue that we have for a per member per month fee. And that's de-linking from the price of drugs. And as you know, that gets a lot of headlines on the PBMs being incentivized by pricing of drugs... that consistent [per-member-per-month fee] delinks us from any pricing changes."

She put the scale in perspective: OptumRx covers "about 61 million lives," fills "1.8 billion prescriptions... per year," and serves "about 5,000 clients," of which it expects "30 to 60 percent" to adopt the new model over the next few years, starting in 2027. She said OptumRx already passes through 99% of manufacturer rebates today and is moving to 100%.

Chuck Melendi, recently retired from Johnson & Johnson, on where the money actually goes. The blunt counterpoint came on Working Healthcare (July 14), where Chuck Melendi, just retired from J&J's advocacy division, walked through the economics that pushed drug prices up in the first place, the incentive to raise a list price so you can hand back a bigger rebate:

"If I raise my price 20% I can give you a 15% rebate and still make 5% on that drug... that's why you saw between 2010 and 2014 drug prices went through the roof."

His headline numbers on who captures the spending: "the manufacturers who do R&D... get less than 50 cents spent on every US dollar on drugs. The majority greater than 50 percent goes to the middleman... whether it's a hospital, PBM, insurer, providers... $850 billion dollars last year went to PBMs." He added that the five largest combined PBM-insurers pull in "over 1.2 trillion dollars" in annual revenue, and that these companies have excluded "600 [to] 900 drugs" from their coverage lists since 2012, sometimes including cheaper generics, because "why would they use a generic when they're not going to get a whole lot of rebates from that."

Eric Lefkofsky, founder of Tempus AI, on ending "trial-and-error" cancer care. On AI and Healthcare (July 10), Eric Lefkofsky, whose company now connects to nearly half of U.S. hospitals, argued that a huge share of cancer deaths come simply from patients being routed to the wrong treatment:

"The patient being on the wrong path, we think accounts for about, give or take roughly, let's say 20% of all fatalities in the U.S. So maybe you could save 100,000 people, 120,000 people a year from dying if we had a system that was using all the information we had and routing people to the right therapeutic... we think you can probably eliminate maybe one in every five cancer deaths."

His broader point: the raw ingredients, cheap gene sequencing, cloud computing, and AI models, have finally come together, and "over the next... three to five years, a tremendous amount of insight" will follow, then "adoption quite quickly thereafter."

The Key Debates

Debate 1: Is UnitedHealth a Turnaround Bargain or a Business Built on Overpayment?

The bull case (a genuine, cheap turnaround): The numbers were startling. UnitedHealth's second-quarter (April–June 2026) adjusted profit came in at $6.38 per share versus about $4.87 expected, a 31% beat, its biggest since 2020, on revenue of $112.03 billion. Management raised full-year profit guidance to $19.50–$20.00 per share, up from "over $18.25," and lifted revenue guidance to about $439 billion. The stock jumped, and Baird flipped from its bearish stance, upgrading to Neutral and lifting its price target from $287 to $453 (Investing.com). Stephanie Link's "still value... I think you should buy it" (Morning Call, July 16) captured the mood. Bulls also point to Optum's $1.5 billion AI investment, which the company claims is returning roughly two dollars for every one spent (The Motley Fool).

The bear case (the model itself is the problem): Dr. Don Berwick's TCN Talks (July 10) argument is the structural rebuttal, that Medicare Advantage plans are paid roughly $80 billion a year more than they should be, and that the very crackdown fixing that overpayment is what crushed the stock in the first place. Two more concerns showed up in the numbers this week: bears warn that automating care decisions with AI invites lawsuits and political backlash, and on its own earnings call UnitedHealth flagged higher cost trends in its employer and commercial insurance, a comment that spooked investors in rivals. Elevance ($ELV) reported a roughly 20% profit beat the same week (adjusted EPS of $7.45) yet its stock fell 8.5%, hurt by cautious guidance, Medicaid exits, and UnitedHealth's cost-trend warning.

Debate 2: When Weight-Loss Drugs Get Cheap, Is That a Threat or a Bigger Opportunity?

The "bigger market" case: Morgan Stanley's India example (Thoughts on the Market, July 13) is the optimistic template, lower prices unlocked six-times-higher volumes and a market on track to grow from $125 million to over $1 billion. In the U.S., cheaper pills and the new Medicare coverage are pulling in first-time users rather than cannibalizing existing ones. And the medical case keeps widening. On Consumerpedia (July 16), endocrinologist Dr. David Cummings, who has treated more than 1,000 patients on these drugs, called them, if anything qualifies, "miracle drugs," citing randomized-trial evidence that they cut heart attacks and strokes, kidney failure, liver disease, and sleep apnea, not just weight. His efficacy scorecard: tirzepatide delivers "about 22% weight loss at about a year," semaglutide about 15%, and a new drug in the pipeline called retatrutide "somewhere between 28% and 30%... knocking at the door where bariatric surgery is" (surgery gets 30–35%).

The "it's complicated" case: Cheaper and broader also means messier. Dr. Cummings was candid that these are "forever drugs," stop taking them and "maybe 75% of the weight that was lost is recovered," along with the health benefits. He also warned that the cheaper compounded and online versions are "a crapshoot whether you're going to get real drug." A striking business wrinkle came from We Fixed It, You're Welcome (July 14), where a researcher named Lisa, who tracks GLP-1 adoption across 60 restaurant brands, said the share of a brand's customers already on these drugs "varies from 12% to 43%," a swing she called the difference between "a niche" and "stop the press, we got to do something different." In other words, the drugs are quietly reshaping how much people eat out, an effect that reaches far beyond the drugmakers. And on the human side, The James Altucher Show (July 16) featured author Charles Duhigg, who has lost 45 pounds on Zepbound over two years, explaining the now-famous "food noise" effect: the drug "opens this habit window... even once you discontinue the medication, the behavior change remains," but only if you actually build new habits while on it.

Debate 3: Are the Drug-System "Middlemen" the Problem, or Part of the Fix?

They capture too much: Chuck Melendi's Working Healthcare (July 14) accounting, manufacturers keep less than 50 cents of every drug dollar, PBMs took in $850 billion last year, and the biggest PBM-insurers gross over $1.2 trillion, is the prosecutor's brief. His most pointed statistic: the net price drugmakers actually receive has fallen for "seven straight years... yet the cost of drugs to patients has gone up." He noted Europe "seems to work pretty well and there are no [PBMs] over there."

They're reforming, sort of: OptumRx's Kate Molander (Prescription for Better Access, July 15) is the defense: a new per-patient fee model that "delinks" PBM revenue from drug prices, plus 100% rebate pass-through. The honest caveat she offered herself: for clients, the change is "financially neutral," "there's not going to be a windfall of value." So it's more transparency than lower cost, at least at first. The two views aren't really opposites: one is about how much the middlemen take, the other about making that take visible.

Debate 4: Big Beats, Muted Reactions, Is This a "Beat and Worry" Earnings Season?

Even good news got a wary reception. Johnson & Johnson ($JNJ) reported a solid quarter, adjusted profit of $2.90 per share versus $2.84 expected, revenue of $25.31 billion (its first quarter ever above $25 billion, keeping it on track to top $100 billion in annual sales for the first time in its 140-year history), and raised its full-year forecast. Yet the stock dipped, because its medical-device arm (especially its Abiomed heart-pump unit) came in unexpectedly soft, overshadowing the strength in its drug business (led by the immunology blockbuster Tremfya). Analysts mostly shrugged and raised targets anyway: Goldman Sachs called the dips "buying opportunities" for a "premier mega-cap secular growth compounder" and lifted its target to $282, while Scotiabank went to $305 and Freedom Broker upgraded to Buy. A market strategist on Morning Call (July 16) summed up the whole season's mood: "from the company's perspective, it is a beat and raise. But from a market participant perspective, it is a beat and worry."

Hot Topics Under Debate

• Eli Lilly's surprise turn into psychedelics. In one of the week's odder deals, Lilly agreed to buy AtaiBeckley ($ATAI) for $6.75 per share in cash plus up to $2.50 more if the drug hits milestones, roughly $2.8 billion upfront, about a 40% premium, for a psychedelic medicine (an intranasal form of 5-MeO-DMT) aimed at treatment-resistant depression (Bloomberg). It lands the same week Lilly won full FDA approval for its cancer drug Retevmo and drew a fresh wave of raised targets (Citi to a Street-high $1,600, UBS to $1,425). The psychedelics theme was echoed on BioSpace (July 15), where analysts described Compass Pathways' depression drug hitting its goal, "almost 40% of patients with treatment-resistant depression... saw a clinically meaningful reduction," with Jefferies "75% to 85% confident" of approval later this year and a launch in the first half of 2027. One psychiatrist quoted on the show said the new class could "wipe out the SSRIs" (today's standard antidepressants) if the safety and durability hold up.

• AstraZeneca's brutal trial failure. The week's sharpest reminder of biotech's downside: AstraZeneca's heart drug Wainua (eplontersen) failed its big late-stage trial in a form of heart disease called ATTR cardiomyopathy, and the stock fell about 12%, erasing a modeled $5 billion-plus in potential peak sales (Perplexity). Its partner, Ionis ($IONS), fell about 35% on the news and was downgraded by Wolfe Research after a second pipeline setback. On Biotech Hangout (July 10), analysts noted the failure "doesn't impact [AstraZeneca's] $80 billion 2030... target" but does raise the stakes for two more trial readouts (in lung and breast cancer) later this year.

• The Vertex bet on rare disease. On Biotech Hangout (July 10), Vertex analyst Paul Bassant broke down the roughly $10 billion purchase of Crinetics (about $9 billion after cash), a near-100% premium for an endocrine-disease company whose lead pipeline drug targets a rare adrenal disorder. His verdict on whether Vertex overpaid: "I almost don't know how much it matters to Vertex if they overpaid by a little," given its $130 billion size and need to add new growth engines beyond cystic fibrosis. Also flagged: Novartis paying $1.1 billion upfront for a private cancer-drug company, Myricx.

• Alzheimer's gets an at-home option. BioSpace (July 15) covered Biogen and Eisai winning early FDA approval for an under-the-skin, at-home version of their Alzheimer's drug Leqembi, ahead of its August PDUFA date. Analysts said it could help Leqembi claw back share from Lilly's rival Kisunla, which still requires infusions and currently holds an estimated 80% of the early-treatment market.

Emerging Themes to Watch

• A new government backstop for weight-loss drugs. The single most important policy change this week barely made the podcasts' front pages but matters enormously: Medicare's new GLP-1 "Bridge Program" launched July 1, letting eligible seniors (roughly, a body-mass index over 35, or over 30 with conditions like heart failure) get Wegovy, Zepbound, and Lilly's new pill Foundayo for a flat $50 monthly copay, with the government having negotiated a net price of about $245 per 30-day supply [kff.org]. It runs through the end of 2027 and, crucially, sits outside the normal Part D system so insurers don't bear the claims risk. For Lilly and Novo Nordisk, it de-risks a big chunk of future U.S. volume. The flip side, flagged on We Fixed It, You're Welcome (July 14): the researcher there noted that even at $50, roughly 11 million seniors still can't afford it.

• AI moving from slideware to real productivity, but show me the numbers. Eric Lefkofsky's Tempus pitch (AI and Healthcare, July 10) is the ambitious version. The skeptical version came from investors themselves: on Biotech Hangout (July 10), an analyst noted big drug companies keep citing a "30% reduction in the time for drug development" from AI, but "we need to see some of those things come through." The gap between the promise and the proof is itself the theme.

• The patent cliff is still the engine under everything. Nearly every deal this week traces back to the same pressure: big drugmakers need to replace revenue from medicines about to lose patent protection late this decade, which keeps small, strategically valuable biotechs in play as takeover targets. Fund flows are following: one bank noted June inflows into biotech and pharma funds were "some of the strongest... in years," though it warned that Q2 earnings would be "an important barometer" and that "strong commercial performance... will be necessary to sustain" the good mood.

• Medical-device makers are the quiet casualties of the GLP-1 boom. A less obvious ripple: investors worry that as weight-loss drugs shrink obesity-linked conditions, they shrink the market for related devices too. ResMed ($RMD), which makes sleep-apnea machines, sank on those fears this week, and Abbott ($ABT) is down more than 28% year-to-date on separate pressures (Kalkine), a reminder that Dr. Cummings' data showing GLP-1s cut sleep apnea is a medical win and a business risk at the same time.

Stocks on the Radar

Tickers that came up most across this week's podcasts and news, with the prevailing tone and why. Direction reflects the tone of this week's commentary, not a recommendation.

Upcoming Catalysts (Next ~2 Weeks)

FDA decisions and clinical data:

• July 17 – Celcuity ($CELC): decision on gedatolisib for advanced breast cancer (link).
• July 18 – Belite Bio: Phase 3 DRAGON data for its Stargardt eye-disease drug at a retina meeting (biopharmawatch.com).
• July 23 – Sanofi: decision on an under-the-skin version of its myeloma drug Sarclisa; Elevar Therapeutics NDA decision.
• July 24 – Otsuka: decision on centanafadine for ADHD.
• July 26 – MannKind ($MNKD): decision on an auto-injector version of its heart-failure drug FUROSCIX.
• July 29 – Outlook Therapeutics ($OTLK): decision on its wet-AMD eye drug.
• July 30 – Viatris ($VTRS): decision on a weekly contraceptive patch.
• ~July 31 – CMS accept/reject window for the second round of Medicare drug-price negotiations, covering 15 drugs including Ozempic, a near-term policy event for the weight-loss/diabetes names [kff.org].
• August 2 – Replimune ($REPL): resubmitted decision on its melanoma therapy RP1.

Earnings (confirmed):

• July 24 – HCA Healthcare (Q2; already pre-warned of a ~$400M policy-related hit) (MarketBeat).
• July 28 – Centene (StockTitan).
• July 29 – Humana (scanx.trade).
• July 30 – Bristol Myers Squibb (BMY IR).
• July 31 – AbbVie (StockTitan).
• Just beyond the window: Merck, Pfizer, and Amgen on Aug 4; CVS and Eli Lilly (a key obesity/diabetes update) on Aug 5; Gilead on Aug 6.

The Bottom Line

This week healthcare did something it hasn't managed in a while: it delivered a genuinely good surprise. UnitedHealth's blowout quarter didn't just lift one stock, it pulled the whole market up and told investors that the sector's most damaged name is healing. But the same week also delivered, on a different podcast, the most detailed case yet for why that business model may be overpaid in the first place. That tension, real operational improvement inside a system many experts think is broken, runs through everything in healthcare right now.

The weight-loss story is following the same arc: the drugs keep proving they do more (hearts, kidneys, livers, sleep), even as prices start to fall and a new government program pulls in millions of new patients. The dealmaking boom rolls on, funded by the patent cliff and now stretching into psychedelics. And the science delivered both a gut-punch (AstraZeneca's failed heart trial) and real progress (at-home Alzheimer's treatment, psychedelic depression drugs, AI-guided cancer care). Earnings season is only half over: Humana, AbbVie, Bristol Myers, and then the giants Merck, Pfizer, Amgen, and Lilly all report over the next three weeks, alongside a July 31 Medicare pricing deadline that hangs over the entire weight-loss complex. If this week's "beat and worry" mood is any guide, the surprises may keep coming, and, as always, the loudest debates are the ones worth watching.